New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLL-37 vs Selank

LL-37 vs Selank

Side-by-side comparison of key properties, dosing, and research.

Immune SupportRecovery & Repair
LL-37
Cognitive Enhancement
Selank
Summary
LL-37 is the only known human cathelicidin antimicrobial peptide. It kills bacteria, fungi, and viruses by disrupting their membranes, while simultaneously modulating immune responses. Used for antimicrobial protection, immune priming, and wound healing.
Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
Half-Life
Very short (~1–2 hours) in plasma due to protease degradation; topical use bypasses systemic clearance
Minutes (but effects persist for hours)
Admin Route
SubQ, Topical, Intranasal
SubQ, Intranasal
Research
Typical Dose
100–300 mcg
250–500 mcg
Frequency
2–3x per week
1–3 times daily
Key Benefits
  • Broad-spectrum antimicrobial (bacteria, fungi, viruses)
  • Promotes wound healing and angiogenesis
  • Immune system modulation — enhances innate immunity
  • Reduces LPS-mediated endotoxemia
  • Anti-biofilm activity against resistant organisms
  • Promotes tissue regeneration and keratinocyte migration
  • May protect against sepsis
  • Reduces anxiety without sedation
  • Enhances memory and learning
  • Improves focus and concentration
  • Stabilizes mood
  • Reduces physiological stress response
  • May enhance motivation
  • No addiction potential or withdrawal
  • Fast-acting — effects within 20–30 minutes
  • Approved clinically in Russia for anxiety disorders
Side Effects
  • Injection site redness and irritation
  • Mild inflammatory response at injection site
  • Potential pro-inflammatory at high doses
  • Rare: fever or flu-like symptoms at initiation
  • Mild sedation at higher doses (paradoxical)
  • Fatigue (rare)
  • Irritability during discontinuation (uncommon)
Stacks With